Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
Conditions: Esophageal Adenocarcinoma; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma Interventions: Drug: OBP-301; Drug: Pembrolizumab Sponsors: Weill Medical College of Cornell University; Merck Sharp& Dohme LLC; Oncolys BioPharma Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | Merck | Research | Study